DUBLIN–(BUSINESS WIRE)–Research and Markets (http://www.researchandmarkets.com/research/gr832s/fabry_disease) has announced the addition of the “Fabry Disease – Pipeline Review, H1 2015” report to their offering. This report provides comprehensive information on the therapeutic […]
Featured Posts
DUBLIN–(BUSINESS WIRE)–Research and Markets (http://www.researchandmarkets.com/research/84dsg4/visceral_pain) has announced the addition of the “Visceral Pain – Pipeline Review, H1 2015” report to their offering. This report provides comprehensive information on the therapeutic […]
The genetically altered, cancer-killing T-cells known as CARTs showed dramatic results in non-Hodgkin lymphoma as the two leading players, the Swiss drug giant Novartis and the Seattle upstart Juno Therapeutics, […]
Former chief scientific officer for Shire Pharmaceuticals and Relmada Therapeutics also headed R&D for Adolor and Stem Cells, Inc.; a trained psychiatrist and CNS specialist, Dr. Salinas arrives as Turing […]
Those with a vested interest in the development of new cancer therapies have been spoiled once again by data presented at the ongoing annual meeting of the American Society of […]
PRINCETON, N.J.–(BUSINESS WIRE)–Bristol-Myers Squibb Company (NYSE:BMY) today announced results from CheckMate -017, a Phase III, open-label, randomized study evaluating Opdivo (n=135) versus docetaxel (n=137) in previously treated patients with advanced […]
A new cancer treatment from Bristol-Myers Squibb saved Gary McLaughlin’s life, but it also landed him in the hospital. McLaughlin, 75, developed melanoma, the deadly skin cancer, just as he was […]
Pharma companies have long demonstrated that they will employ questionable marketing and sales tactics to boost sales, no matter what the impact is on patients’ health. Now Amarin, a small […]
Once-Daily, Dual Mechanism Antibiotic Possesses Profile to Play Key Role in Global Fight Against Antimicrobial Resistance FOSTER CITY, CA and GEORGE TOWN, GRAND CAYMAN–(Marketwired – May 27, 2015) – SciClone […]
ELSTREE, U.K. & DURHAM, N.C.–(BUSINESS WIRE)–Bio Products Laboratory, Ltd. (BPL), a leading manufacturer of plasma-derived therapies, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review […]